DB:337

Stock Analysis Report

Corbus Pharmaceuticals Holdings

Executive Summary

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Corbus Pharmaceuticals Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 337's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.9%

337

3.0%

DE Biotechs

9.1%

DE Market


1 Year Return

-25.4%

337

-9.5%

DE Biotechs

-13.1%

DE Market

Return vs Industry: 337 underperformed the German Biotechs industry which returned -9% over the past year.

Return vs Market: 337 underperformed the German Market which returned -14.3% over the past year.


Shareholder returns

337IndustryMarket
7 Day-0.9%3.0%9.1%
30 Day19.1%1.5%-1.0%
90 Day-15.2%-23.9%-20.7%
1 Year-25.4%-25.4%-9.2%-9.5%-10.6%-13.1%
3 Year-26.8%-26.8%17.1%15.9%-10.7%-18.1%
5 Yearn/a-8.7%-11.1%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is Corbus Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Corbus Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 337 (€4.62) is trading below our estimate of fair value (€43.6)

Significantly Below Fair Value: 337 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 337 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 337 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 337's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 337 is overvalued based on its PB Ratio (54.9x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Corbus Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

56.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 337 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 337 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 337 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 337's revenue (56.1% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: 337's revenue (56.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 337's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Corbus Pharmaceuticals Holdings performed over the past 5 years?

-46.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 337 is currently unprofitable.

Growing Profit Margin: 337 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 337 is unprofitable, and losses have increased over the past 5 years at a rate of -46.5% per year.

Accelerating Growth: Unable to compare 337's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 337 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.9%).


Return on Equity

High ROE: 337 has a negative Return on Equity (-1160.42%), as it is currently unprofitable.


Next Steps

Financial Health

How is Corbus Pharmaceuticals Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 337's short term assets ($38.2M) exceed its short term liabilities ($34.9M).

Long Term Liabilities: 337's short term assets ($38.2M) exceed its long term liabilities ($8.1M).


Debt to Equity History and Analysis

Debt Level: 337's debt to equity ratio (12.2%) is considered satisfactory.

Reducing Debt: 337's debt to equity ratio has increased from 2.5% to 12.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 337 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 337 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -44% each year


Next Steps

Dividend

What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 337's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 337's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 337's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 337's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 337's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Yuval Cohen (44yo)

6s

Tenure

US$3,572,460

Compensation

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc  ...


CEO Compensation Analysis

Compensation vs Market: Yuval's total compensation ($USD3.57M) is above average for companies of similar size in the German market ($USD1.11M).

Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Yuval Cohen
CEO & Director6yrsUS$3.57m0.098% $341.9k
Mark Tepper
Co-Founder & Consultant1yrUS$1.66m2.91% $10.1m
Barbara White
Head of Research & Chief Medical Officer5.67yrsUS$1.69m0.28% $991.8k
Sean Moran
Chief Financial Officer6yrsUS$1.24m0.48% $1.7m
Robert Discordia
Chief Operating Officerno datano data0.049% $170.7k
Ted Jenkins
Senior Director of Investor Relations & Communicationsno datano datano data
Scott Constantine
Senior Director & Head of Clinical Operationsno datano datano data
Craig Millian
Chief Commercial Officer1.17yrsno data0.017% $57.7k
Sergei Atamas
Executive Director of Researchno datano datano data

5.7yrs

Average Tenure

61yo

Average Age

Experienced Management: 337's management team is seasoned and experienced (5.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yuval Cohen
CEO & Director6yrsUS$3.57m0.098% $341.9k
Avery Catlin
Independent Director5.67yrsUS$213.62k0.065% $226.1k
David Hochman
Director6.33yrsUS$205.20k0.97% $3.4m
Alan Holmer
Chairman6yrsUS$238.71k0.031% $108.2k
Charles Serhan
Member of Scientific Advisory Board4.92yrsno datano data
George Kunos
Member of Scientific Advisory Board1.58yrsno datano data
Michael Knowles
Member of Scientific Advisory Boardno datano datano data
John Jenkins
Independent Director1.83yrsUS$325.35k0.0014% $4.8k
Rachelle Jacques
Independent Director1yrno datano data
Peter Salzmann
Director0.083yrno datano data

4.9yrs

Average Tenure

51yo

Average Age

Experienced Board: 337's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 337 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.


Top Shareholders

Company Information

Corbus Pharmaceuticals Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corbus Pharmaceuticals Holdings, Inc.
  • Ticker: 337
  • Exchange: DB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$379.125m
  • Listing Market Cap: US$348.643m
  • Shares outstanding: 72.49m
  • Website: https://www.corbuspharma.com

Number of Employees


Location

  • Corbus Pharmaceuticals Holdings, Inc.
  • 500 River Ridge Drive
  • Norwood
  • Massachusetts
  • 2062
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRBPNasdaqGM (Nasdaq Global Market)YesNew Common SharesUSUSDOct 2014
337DB (Deutsche Boerse AG)YesNew Common SharesDEEUROct 2014
0SZILSE (London Stock Exchange)YesNew Common SharesGBUSDOct 2014

Biography

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 23:44
End of Day Share Price2020/04/08 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.